Bansisons Tea Industries Approves Major Corporate Changes, Including Name Change and Land Sale

1 min read Updated on 19 Nov 2025, 04:34 PM

Reviewed by

Shriram ShekharScanX News Team

Overview

Bansisons Tea Industries Limited announced significant corporate changes following a board meeting. The company plans to change its name to either 'Quantum Care Pharmachem Limited' or 'Novyra Pharmachem Limited', modify its object clause, and sell company land. These decisions indicate a potential shift from tea to pharmaceuticals. Mrs. Mamy Ghosh resigned as an Independent Director. The company will seek shareholder approval for these changes through a postal ballot.

*this image is generated using AI for illustrative purposes only.

Bansisons Tea Industries Limited (BSE: 519353) has announced significant corporate changes following a board meeting held on November 19, 2025. The company's board has approved several key decisions that may reshape its business focus and structure.

Key Corporate Changes

Decision	Details	Approval Required
Name Change	From "Bansisons Tea Industries Limited" to "Quantum Care Pharmachem Limited" or "Novyra Pharmachem Limited"	Shareholders via Postal Ballot
Object Clause Modification	Change in the Memorandum of Association	Shareholders via Postal Ballot
Land Sale	Approval for sale of company land under Section 180(1)(a) of Companies Act, 2013	Shareholders via Postal Ballot

These decisions signal a potential shift in the company's core business from tea to pharmaceuticals, as reflected in the proposed name changes.

Board Changes

Mrs. Mamy Ghosh (DIN: 06532484) has resigned from her position as an Independent Director, effective November 19, 2025, citing pre-occupation as the reason for her departure.

Postal Ballot and Shareholder Approval

The board has approved a draft notice for a postal ballot to seek shareholder consent for the aforementioned changes. The company plans to submit the notice to the stock exchanges in compliance with SEBI Listing Regulations. Mrs. Rupal Patel, a practicing Company Secretary, has been appointed as the scrutinizer for the postal ballot process.

Implications

These corporate actions, particularly the name change and object clause modification, suggest a potential strategic pivot for Bansisons Tea Industries. The move towards a pharmaceutical-oriented name and business object indicates a possible significant transformation in the company's future direction.

The approval for land sale could potentially provide the company with additional capital to fund this transition or strengthen its financial position.

Investors and stakeholders may want to closely monitor further announcements and the outcome of the postal ballot, as these changes could substantially impact the company's business model and future prospects.

The board meeting, which commenced at 3:00 p.m. and concluded at 4:00 p.m., marks a pivotal moment in the company's history. As these changes require shareholder approval, the coming weeks will be crucial in determining the potential new direction of Bansisons Tea Industries Limited.

Historical Stock Returns for Bansisons Tea Industries